Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Nausea and Vomiting Post-foregut Surgery
Interventions
Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge
Device · Drug
Lead sponsor
Kyle A Perry
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Pancreatic Cancer
Interventions
Intravenous Vitamin C, Gemcitabine
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Postoperative Nausea
Interventions
Fosaprepitant 150 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Advanced Cancer
Interventions
Olanzapine, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Capecitabine, Premedication
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more
Conditions
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions
Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Conditions
Breast Cancer, Nausea, Vomiting
Interventions
granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Graft-Versus-Host Disease(GVHD)
Interventions
5-Azacytidine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Houston, Texas
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Nausea, Vomiting, Childhood Cancer
Interventions
Ondansetron, dexamethasone, aprepitant, Ondansetron, Dexamethasone, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Months to 20 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Non Small Cell Lung Carcinoma
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
Instituto Nacional de Cancer, Brazil
Government
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami Beach, Florida
Completed Not applicable Interventional Results available

Acupuncture and Nausea/Vomiting in Pediatric Patients

NCT01417741
Conditions
Postoperative Vomiting and Nausea
Interventions
Acupuncture Needle
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Years to 9 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Conditions
Cancer, Stress
Interventions
Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT), Usual Care Only
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial

NCT02456662
Conditions
Drug-induced Nausea and Vomiting
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, New York
Conditions
Safety, and Tolerability
Interventions
DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
Combination Product · Drug
Lead sponsor
Aspeya Switzerland SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Interventions
Olanzapine, Placebo Oral Tablet
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
30 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more
Conditions
Advanced Solid Tumours
Interventions
AZD1775, MEDI4736
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Conditions
Gastroesophageal Cancer
Interventions
Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more
Conditions
Nausea
Interventions
Peppermint oil, Ginger oil
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, New York
Terminated Phase 2 Interventional Results available

Low Dose Aprepitant for Patients Receiving Carboplatin

NCT03237611
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
The Bronx, New York
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy Volunteers
Interventions
Sancuso - Part 1, Sancuso - Part 2
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas